News for Healthier Living

Novel Antibody-Drug Conjugate Eliminates Residual Cancer Cells in Majority of Patients with B-Cell ALL

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

July 7, 2026


July 8 2026

July 7 2026

July 6 2026

July 3 2026

July 2 2026

July 1 2026

June 30 2026

June 29 2026

June 26 2026

June 25 2026

June 24 2026